Xiang Wang

First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial

Lin Wang, Xuezhi Hao, Yanrong Hao, Yanping Hu et autres

cn, hk (code pays fourni par la source)

JSKN003, a biparatopic HER2-targeting ADC, in heavily pretreated HER2-positive breast cancer: A pooled analysis of early-phase studies.

Yiqun Du, Jian Zhang, Jieqiong Liu, Wenfeng Li et autres

1028 Background: JSKN003 is a biparatopic HER2-targeting antibody-drug conjugate (ADC) conjugated to a topoisomerase I inhibitor (TOP1i) via a tetrapeptide linker, designed to enhance serum stability and anti-tumor activity. The efficacy and safety of JSKN003 in advanced ovarian cancer and other solid …

cn, au (code pays fourni par la source)

Efficient production of 2′-fucosyllactose in Pichia pastoris through metabolic engineering and constructing an orthogonal energy supply system

Yi Li, Xiang Wang, Kaidi Chen, Zhoukang Zhuang et autres

2′-fucosyllactose (2′-FL) holds significant role in the infants' nutrition. While microbial production of 2′-FL has predominantly utilized Escherichia coli and Saccharomyces cerevisiae , the potential of Pichia pastoris , renowned for its robust NADPH regeneration capability, remains underexplored. Herein, we systematically engineered …

cn (code pays fourni par la source)

A narrative review of preoperative CT for predicting spread through air spaces of lung cancer

Qinling Jiang, Xiang Wang, Hongbiao Sun, Qi Chen et autres

Background and Objective: Spread through air space (STAS) is a recognized mechanism of lung cancer invasion and is associated with patient prognosis. However, current diagnostic accuracy of bronchial cytology and intraoperative frozen section for STAS remains insufficient to meet clinical needs. Therefore, …

cn (code pays fourni par la source)

Key role of sulfur in sulfidated zerovalent iron during persulfate activation for the dynamic equilibrium of oxidative radicals including SO4•- and •OH

Xuyun Gao, Xiang Wang, Zihan Zhuang, Xike Tian et autres

cn (code pays fourni par la source)

Abstract PS08-08: Updated efficacy and safety of SKB264 (MK-2870) for previously treated metastatic triple negative breast cancer (mTNBC) in Phase 2 study

Yongmei Yin, Xinhong Wu, Quchang Ouyang, Min Yan et autres

Abstract Background: Patients (pts) with mTNBC have limited treatment options and poor prognosis. The estimated median overall survival (OS) of pts with mTNBC is 12 to 18 months (mo) after diagnosis. SKB264, an antibody drug conjugate (ADC) composed of an anti-TROP2 antibody …

cn, gb (code pays fourni par la source)

Abstract CT038: Preliminary efficacy and safety results of anti-TROP2 ADC SKB264 (MK-2870) in patients (pts) with previously treated advanced gastric (G) or gastroesophageal junction (GEJ) cancer from a Phase 2 study

Jordi A. Rodon, Zev A. Wainberg, Mingjun Zhang, Tianshu Liu et autres

Abstract Background: Overexpression of TROP2 (trophoblast cell surface antigen 2) in advanced gastric cancer is known as a poor prognostic factor. SKB264 (MK-2870) is a TROP2 ADC developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor. The …

us, cn (code pays fourni par la source)

Abstract CT247: Updated efficacy and safety of anti-TROP2 ADC SKB264 (MK-2870) for previously treated advanced NSCLC in Phase 2 study

Wenfeng Fang, Ying Cheng, Zhendong Chen, Wei Wang et autres

Abstract Background: TROP2 (trophoblast cell surface antigen 2) is commonly over-expressed in non-small cell lung cancer (NSCLC) and associated with poor prognosis. SKB264 (MK-2870) is a TROP2 ADC developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor. …

cn, us (code pays fourni par la source)

Abstract CT246: Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer

Ziming Li, Xiaomin Dang, Dingzhi Huang, Jin Shi et autres

Abstract Background: Garsorasib (D-1553), a potent KRAS G12C inhibitor, has previously demonstrated promising anti-tumor activity in KRAS G12C-mutated non-small-cell lung cancer (NSCLC) in a phase 1 study. Here we present the efficacy and safety of garsorasib in a pivotal phase 2 study. …

cn (code pays fourni par la source)

A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)

Caicun Zhou, Yanping Hu, Ekaterine Arkania, Saadettin Kılıçkap et autres

cn, ge, tr, us (code pays fourni par la source)

Patient-reported outcomes of furmonertinib versus gefitinib in patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 study.

Yuankai Shi, Gongyan Chen, Xiang Wang, Yunpeng Liu et autres

9081 Background: Furmonertinib showed superior efficacy compared with gefitinib as first-line therapy in Chinese patients with EGFR mutation-positive non-small cell lung cancer (NSCLC), along with an acceptable safety profile without new signals in the FURLONG study. Here we present patient-reported outcomes (PROs). …

cn (code pays fourni par la source)

SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study.

Wen‐Feng Fang, Ying Cheng, Zhendong Chen, Wei Wang et autres

9114 Background: TROP2 (trophoblast cell surface antigen 2) is commonly overexpressed in non-small cell lung cancer (NSCLC) and associated with poor prognosis. SKB264 is a novel anti-TROP2 ADC developed using sulfonyl pyrimidine-CL2A-carbonate linker to conjugate its payload, a belotecan-derivative topoisomerase I inhibitor, …

cn, us (code pays fourni par la source)